Video guide
In 24 trials, women on a dummy pill saw hot flashes fall 57.7%. The 2023 Menopause Society position statement sorts which non-hormone options actually have evidence.
Published
In 24 trials, women on a dummy pill saw hot flashes fall 57.7%.
That’s why a remedy only counts if it beats the dummy pill. Here’s how the 2023 Menopause Society position statement sorted some of the non-hormone options. Talk to your doctor about what fits you.
Women on placebo saw hot flashes fall 57.7% from start to end of study (24 trials, 3,329 women)
MacLennan et al., Cochrane Database of Systematic Reviews, 2004Recommended non-hormone options: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant
The North American Menopause Society, Menopause, 2023Not recommended: paced breathing, herbal remedies, soy, acupuncture
The North American Menopause Society, Menopause, 2023Hormone therapy remains the most effective treatment
The North American Menopause Society, Menopause, 2023MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978.
Read the sourceThe 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
Read the sourceNumbers are rounded the way the original source reports them. If you spot an error, email admin@svarene.com and we will correct it.
Available now on iPhone and Android
Private by design. Built for perimenopause. Ready when you are.
Privacy at a glance
Core health logs stay on-device.
Optional services use only the limited information they need.
No data sales. No ads. No advertising tracking.
